TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind Randomised, Placebo-controlled Study of Adjunctive Ketamine Anaesthesia in ECT (Electroconvulsive Therapy)
Brief Summary: Research into the mechanisms underlying memory impairment in ECT suggests that its development may be prevented by the administration of certain medications at the time of ECT treatment. For example there are reasons to believe that ketamine, also used as an anaesthetic agent, may have such protective properties.

In this clinical study patients undergoing a course of ECT will be offered the opportunity to receive a small dose of ketamine (or a placebo) as part of their anaesthetic at the time of ECT treatment. Mood changes and any memory changes will be evaluated to see if the subjects who received ketamine had less memory side effects than those who did not, while still improving their depression.


Options:
A: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Ketamine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Placebo
B: Arm Label: AZD6765 (150 mg) / Placebo; Type: EXPERIMENTAL; Interventions: Drug: AZD6765 | Arm Label: Placebo / AZD6765 (150 mg); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to AZD6765 | Intervention Type: DRUG; Name: AZD6765; Assigned to Arm(s): AZD6765 (150 mg) / Placebo | Intervention Type: DRUG; Name: Placebo to AZD6765; Assigned to Arm(s): Placebo / AZD6765 (150 mg)
C: Arm Label: sarcosine; Type: EXPERIMENTAL; Interventions: Drug: sarcosine | Arm Label: citalopram; Type: ACTIVE_COMPARATOR; Interventions: Drug: citalopram | Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): citalopram | Intervention Type: DRUG; Name: sarcosine; Assigned to Arm(s): sarcosine
D: Arm Label: A: Ketamine + Naltrexone or placebo; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone | Arm Label: B: Ketamine + Naltrexone or placebo; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): A: Ketamine + Naltrexone or placebo, B: Ketamine + Naltrexone or placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind Randomised, Placebo-controlled Study of Adjunctive Ketamine Anaesthesia in ECT (Electroconvulsive Therapy)
Brief Summary: Research into the mechanisms underlying memory impairment in ECT suggests that its development may be prevented by the administration of certain medications at the time of ECT treatment. For example there are reasons to believe that ketamine, also used as an anaesthetic agent, may have such protective properties.

In this clinical study patients undergoing a course of ECT will be offered the opportunity to receive a small dose of ketamine (or a placebo) as part of their anaesthetic at the time of ECT treatment. Mood changes and any memory changes will be evaluated to see if the subjects who received ketamine had less memory side effects than those who did not, while still improving their depression.


Options:
A: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Ketamine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Placebo
B: Arm Label: Placebo then MK-0657; Type: EXPERIMENTAL; Interventions: Drug: MK-0657, Drug: Placebo | Arm Label: MK-0657 then Placebo; Type: EXPERIMENTAL; Interventions: Drug: MK-0657, Drug: Placebo | Intervention Type: DRUG; Name: MK-0657; Assigned to Arm(s): MK-0657 then Placebo, Placebo then MK-0657 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): MK-0657 then Placebo, Placebo then MK-0657
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Ketamine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Midazolam | Intervention Type: DRUG; Name: Ketamine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Midazolam; Assigned to Arm(s): 2
D: Arm Label: Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: GLYX-13 | Arm Label: GLYX-13, 1 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: GLYX-13 | Arm Label: GLYX-13, 5 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: GLYX-13 | Arm Label: GLYX-13, 10 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: GLYX-13 | Intervention Type: DRUG; Name: GLYX-13; Assigned to Arm(s): GLYX-13, 1 mg/kg, GLYX-13, 10 mg/kg, GLYX-13, 5 mg/kg, Normal Saline

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Tenecteplase to Treat Severe Submassive Pulmonary Embolism
Brief Summary: The purpose of this study is to determine if tenecteplase plus enoxaparin is safe and effective in the treatment of patients with severe submassive pulmonary embolism.


Options:
A: Intervention Type: DRUG; Name: tenecteplase; Assigned to Arm(s): N/A
B: Arm Label: Group 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Urokinase | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Drug: Urokinase | Intervention Type: DRUG; Name: Urokinase; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Urokinase; Assigned to Arm(s): Group 2
C: Arm Label: group A; Type: EXPERIMENTAL; Interventions: Drug: tenecteplase (group A) | Arm Label: group B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo ( group B) | Intervention Type: DRUG; Name: placebo ( group B); Assigned to Arm(s): group B | Intervention Type: DRUG; Name: tenecteplase (group A); Assigned to Arm(s): group A
D: Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline + Enoxaparin | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Tenecteplase + Enoxaparin | Intervention Type: DRUG; Name: Tenecteplase + Enoxaparin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: 0.9% Saline + Enoxaparin; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Tenecteplase to Treat Severe Submassive Pulmonary Embolism
Brief Summary: The purpose of this study is to determine if tenecteplase plus enoxaparin is safe and effective in the treatment of patients with severe submassive pulmonary embolism.


Options:
A: Arm Label: A-Intervention; Type: EXPERIMENTAL; Interventions: Drug: Recombinant tissue plasminogen activator (rt-PA) | Arm Label: B-Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Recombinant tissue plasminogen activator (rt-PA); Assigned to Arm(s): A-Intervention
B: Arm Label: Ultrasound accelerated thrombolysis; Type: EXPERIMENTAL; Interventions: Device: EkoSonic Endovascular System | Arm Label: Intravenous unfractionated heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated heparin | Intervention Type: DEVICE; Name: EkoSonic Endovascular System; Assigned to Arm(s): Ultrasound accelerated thrombolysis | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): Intravenous unfractionated heparin
C: Intervention Type: DRUG; Name: tenecteplase; Assigned to Arm(s): N/A
D: Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline + Enoxaparin | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Tenecteplase + Enoxaparin | Intervention Type: DRUG; Name: Tenecteplase + Enoxaparin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: 0.9% Saline + Enoxaparin; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of Tenecteplase to Treat Severe Submassive Pulmonary Embolism
Brief Summary: The purpose of this study is to determine if tenecteplase plus enoxaparin is safe and effective in the treatment of patients with severe submassive pulmonary embolism.


Options:
A: Arm Label: EkoSonic® Endovascular System; Type: EXPERIMENTAL; Interventions: Drug: recombinant tissue plasminogen activator, Device: EKOS EkoSonic Endovascular System | Intervention Type: DRUG; Name: recombinant tissue plasminogen activator; Assigned to Arm(s): EkoSonic® Endovascular System | Intervention Type: DEVICE; Name: EKOS EkoSonic Endovascular System; Assigned to Arm(s): EkoSonic® Endovascular System
B: Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline + Enoxaparin | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Tenecteplase + Enoxaparin | Intervention Type: DRUG; Name: Tenecteplase + Enoxaparin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: 0.9% Saline + Enoxaparin; Assigned to Arm(s): 2
C: N/A
D: Arm Label: group A; Type: EXPERIMENTAL; Interventions: Drug: tenecteplase (group A) | Arm Label: group B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo ( group B) | Intervention Type: DRUG; Name: placebo ( group B); Assigned to Arm(s): group B | Intervention Type: DRUG; Name: tenecteplase (group A); Assigned to Arm(s): group A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preventing Excessive Weight Gain in Adolescent Girls at High-Risk for Adult Obesity
Brief Summary: This study will examine whether interpersonal psychotherapy (IPT) can help reduce excessive weight gain in adolescent girls. It will compare the effectiveness of IPT with a teen health education program in preventing weight gain.

Adolescent girls between 12 and 17 years of age who are at risk for becoming overweight adults, by virtue of being above average weight and experiencing episodes of loss of control over eating, may be eligible for this study. Candidates are screened in two visits with the following procedures:

Visit 1

* Height and weight measurements.
* Interview and questionnaires about the child s general health, social and psychological functioning and eating patterns and behaviors.

Visit 2

* Physical examination, blood and urine tests.
* DXA scan to measure body fat, muscle and bone mineral content.
* Laboratory test meal. The child fills out a rating scale about her level of hunger and is then given a food buffet from which she is instructed to eat as much as she wants. Immediately after eating, the child again completes the hunger rating forms.
* Interview about the child s mood and psychological functioning.

Participants are assigned at random to either the IPT or teen health education program. All participants have a 1- to 1 1/2-hour individual session with a therapist, followed by 12 weekly group sessions of 1 1/2 hours each in their assigned program. They are assessed at the end of the program with questionnaires and body measurements. They return to the clinic after 6 months for body measurements, blood test, DXA scan, questionnaires, interview and a test meal, and again at 1 year for body measurements, questionnaires and a DXA scan.


Options:
A: Intervention Type: DRUG; Name: glucophage XR; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Interpersonal Psychotherapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Health Education; Assigned to Arm(s): N/A
C: Arm Label: Sibutramine; Type: EXPERIMENTAL; Interventions: Drug: Sibutramine hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Lead-in sibutramine; Type: EXPERIMENTAL; Interventions: Drug: Sibutramine hydrochloride | Intervention Type: DRUG; Name: Sibutramine hydrochloride; Assigned to Arm(s): Sibutramine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Sibutramine hydrochloride; Assigned to Arm(s): Lead-in sibutramine
D: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mechanisms of Meditation in Hypertension in Blacks
Brief Summary: High blood pressure is a common health problem among people in the United States. This study will compare the effectiveness of a meditation program versus a health education program at decreasing stress and lowering blood pressure levels among African-American adults with high blood pressure.


Options:
A: Arm Label: Early Intervention, MBSR therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness Based Stress Reduction (MBSR) Therapy | Arm Label: Delayed Treatment Arm, MBSR Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mindfulness Based Stress Reduction (MBSR) Therapy | Intervention Type: BEHAVIORAL; Name: Mindfulness Based Stress Reduction (MBSR) Therapy; Assigned to Arm(s): Delayed Treatment Arm, MBSR Therapy, Early Intervention, MBSR therapy
B: Arm Label: Stress reduction; Type: EXPERIMENTAL; Interventions: Behavioral: Transcendental Meditation | Arm Label: health education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Education | Intervention Type: BEHAVIORAL; Name: Transcendental Meditation; Assigned to Arm(s): Stress reduction | Intervention Type: BEHAVIORAL; Name: Health Education; Assigned to Arm(s): health education
C: Arm Label: Mindfulness-based Addiction Treatment (MBAT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mindfulness-based Addiction Treatment, Behavioral: Self-Help guide, Drug: Nicotine Patch | Arm Label: iQuit Mindfully; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness-based Addiction Treatment, Behavioral: iQuit Mindfully, Behavioral: Self-Help guide, Drug: Nicotine Patch | Intervention Type: BEHAVIORAL; Name: Mindfulness-based Addiction Treatment; Assigned to Arm(s): Mindfulness-based Addiction Treatment (MBAT), iQuit Mindfully | Intervention Type: BEHAVIORAL; Name: iQuit Mindfully; Assigned to Arm(s): iQuit Mindfully | Intervention Type: BEHAVIORAL; Name: Self-Help guide; Assigned to Arm(s): Mindfulness-based Addiction Treatment (MBAT), iQuit Mindfully | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Mindfulness-based Addiction Treatment (MBAT), iQuit Mindfully
D: Arm Label: Enhanced health education program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced health education | Arm Label: Transcendental Meditation program; Type: EXPERIMENTAL; Interventions: Behavioral: Transcendental Meditation program | Intervention Type: BEHAVIORAL; Name: Enhanced health education; Assigned to Arm(s): Enhanced health education program | Intervention Type: BEHAVIORAL; Name: Transcendental Meditation program; Assigned to Arm(s): Transcendental Meditation program

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tacrolimus and Mycophenolate Versus Tacrolimus and Sirolimus vs. Neoral and Sirolimus Used in Combination in Cadaver and Non-HLA Identical Living Related Kidney Transplants
Brief Summary: Comparison of outcomes/safety/and tolerability of SRL/FK/Pred vs. FK/MMF/Pred vs. SRL/Neoral®/Pred in cadaveric and non-HLA identical LRD kidney transplants.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rituximab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: rabbit anti-thymocyte globulin - single dose, Drug: sirolimus, Drug: tacrolimus | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Drug: rabbit anti-thymocyte globulin - 4 doses, Drug: sirolimus, Drug: tacrolimus | Arm Label: Group 3; Type: EXPERIMENTAL; Interventions: Drug: rabbit anti-thymocyte globulin - single dose, Drug: mycophenolate mofetil, Drug: sirolimus, Drug: tacrolimus | Arm Label: Group 4; Type: EXPERIMENTAL; Interventions: Drug: mycophenolate mofetil, Drug: rabbit anti-thymocyte globulin - 4 doses, Drug: sirolimus, Drug: tacrolimus | Intervention Type: DRUG; Name: rabbit anti-thymocyte globulin - single dose; Assigned to Arm(s): Group 1, Group 3 | Intervention Type: DRUG; Name: mycophenolate mofetil; Assigned to Arm(s): Group 3, Group 4 | Intervention Type: DRUG; Name: rabbit anti-thymocyte globulin - 4 doses; Assigned to Arm(s): Group 2, Group 4 | Intervention Type: DRUG; Name: sirolimus; Assigned to Arm(s): Group 1, Group 2, Group 3, Group 4 | Intervention Type: DRUG; Name: tacrolimus; Assigned to Arm(s): Group 1, Group 2, Group 3, Group 4
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Tacrolimus/Sirolimus | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Tacrolimus/MMF | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Neoral/Sirolimus | Intervention Type: DRUG; Name: Tacrolimus/Sirolimus; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Tacrolimus/MMF; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Neoral/Sirolimus; Assigned to Arm(s): C
D: Arm Label: Campath-1H 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Alemtuzumab | Arm Label: Tacrolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tacrolimus | Arm Label: Campath-1H 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Alemtuzumab | Intervention Type: DRUG; Name: Alemtuzumab; Assigned to Arm(s): Campath-1H 20 mg | Intervention Type: DRUG; Name: Tacrolimus; Assigned to Arm(s): Tacrolimus | Intervention Type: DRUG; Name: Alemtuzumab; Assigned to Arm(s): Campath-1H 30 mg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study to Evaluate the Efficacy, Tolerability, Safety, and Pharmacokinetics of 4975 in Patients Undergoing Primary Unilateral Total Knee Arthroplasty
Brief Summary: Evaluate the efficacy, tolerability, safety, and pharmacokinetics of 4975 in patients undergoing total knee replacement


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vitamin Complex (placebo) | Arm Label: Pregabalin; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: Vitamin Complex (placebo); Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: morphine and mexiletine; Assigned to Arm(s): N/A
C: Arm Label: Injection with Saline; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Infiltration with Saline | Arm Label: Injection with Bupivacaine; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Infiltration with Bupivacaine | Intervention Type: PROCEDURE; Name: Infiltration with Saline; Assigned to Arm(s): Injection with Saline | Intervention Type: PROCEDURE; Name: Infiltration with Bupivacaine; Assigned to Arm(s): Injection with Bupivacaine
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: 4975, 15 and 5 mg | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Comparator | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: 4975 - 5 mg | Intervention Type: DRUG; Name: 4975, 15 and 5 mg; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo Comparator; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: 4975 - 5 mg; Assigned to Arm(s): 3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Omega 3 Fish Oil Supplements vs. Placebo for Patients With Non-alcoholic Steatohepatitis (NASH)
Brief Summary: Nonalcoholic steatohepatitis (NASH) occurs in 2-3% of the US population and carries a 15-20% chance of progression to cirrhosis. It is closely associated with obesity, hyperlipidemia and insulin resistance. Therapy usually includes recommendations to increase exercise and to begin weight reducing diets but these goals are variably achieved and their relative effects in conjunction with pharmacological intervention have not been well defined. Moreover, these lifestyle changes can confound results of treatment trials if not quantified through conditioning testing and measures of body fat. Polyunsaturated fatty acids, especially formulation rich in omega-3, are widely accepted and endorsed in the medical community for their beneficial effects on hyperlipidemia and coronary disease risk reduction. Recent data suggests that omega-3 fatty acids ameliorate hepatic steatosis in humans and in animal models of NASH by reducing hepatic fat content. We hypothesize that a one year course of omega-3 fatty acid (3gm/day) will produce improvement in NASH histological injury independent of changes in weight (BMI) or degree of conditioning measured by the lactate threshold. The effects of the supplement will be compared to a placebo group and controlled for these lifestyle changes.


Options:
A: Arm Label: OMEGA-3; Type: ACTIVE_COMPARATOR; Interventions: Drug: OMEGA-3 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo soybean oil | Intervention Type: DRUG; Name: OMEGA-3; Assigned to Arm(s): OMEGA-3 | Intervention Type: DRUG; Name: Placebo soybean oil; Assigned to Arm(s): Placebo
B: Arm Label: Omega 3 recipient arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omega 3 Fish Oil supplements | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Omega 3 Fish Oil supplements; Assigned to Arm(s): Omega 3 recipient arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1 Epanova; Type: EXPERIMENTAL; Interventions: Drug: Epanova | Arm Label: 2 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Epanova | Intervention Type: DRUG; Name: Epanova; Assigned to Arm(s): 1 Epanova, 2 Placebo
D: Arm Label: Lower fat diet; Type: EXPERIMENTAL; Interventions: Behavioral: Weight loss | Arm Label: Lower carbohydrate diet; Type: EXPERIMENTAL; Interventions: Behavioral: Weight loss | Arm Label: Walnut-rich diet; Type: EXPERIMENTAL; Interventions: Behavioral: Weight loss | Intervention Type: BEHAVIORAL; Name: Weight loss; Assigned to Arm(s): Lower carbohydrate diet, Lower fat diet, Walnut-rich diet

Answer: B